Angiotensin II receptor blockers: Novel therapy for heart failure?

Pharmacotherapy

Volumn 16, Issue 2 II, 1996, Pages

  Munger, Mark A ^a,b   Furniss, Shawn M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN III; ANGIOTENSINOGEN; BRADYKININ; CHYMASE; KALLIKREIN; LOSARTAN; RENIN;

ALDOSTERONE BLOOD LEVEL; APOPTOSIS; ARTICLE; EXERCISE TOLERANCE; HEART FAILURE; HEART PROTECTION; HUMAN; MORTALITY; MUSCLE DEVELOPMENT; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL TIME;

ADULT; AMINO ACID SEQUENCE; CARDIAC OUTPUT, LOW; HEART FAILURE, CONGESTIVE; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, ANGIOTENSIN;

EID: 0029873918     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 1993;88.107-15
2. Lindpainter K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991;68:905-21.
3. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasis. Circ Res 1993;72:1245-54
4. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 1993;72:1202-10
5. The CONSENSUS Trial Study Group. Effects of enalapnl on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987,316-1429-35.
6. The Captopril-Digoxin Multicenter Research Group. Comparative effects of captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-44.
7. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 1991;325:303-10.
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 1991;325 293-302.
9. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction N Engl J Med 1992;327 685-91
10. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopnl on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327: 669-77
11. Urata H, Healy JB, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts Circ Res 1990;66:883-90.
12. Urata H, Boehm KD, Philip A, et al Cellular localization and regional distribution of an angiotensin-II forming chymase in the heart. J Clin Invest 1993;91.1269-81.
13. Pouleur H, Konstram MA, Benedict CR, et al. Progression of left ventricular dysfunction during enalapril therapy, relationship with neurohormonal reactivation Circulation 1993;88:I-293A.
14. Aldigier JC, Huang H, Dalmay F, et al. Angiotensin converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardtovasc Pharmacol 1993;21 289-95
15. Merill AJ, Morrison JR, Brannon ES. Concentration of renin in renal venous blood in patients with congestive heart failure. Am J Med 1946,1:468-72
16. Keeton TK, Campbell WB. The pharmacologic alteration of renin release. Pharmacol Rev 1980,32:80-4.
17. Bunag RD, Page IH, McCubbin JW. Neural stimulation of release of renin Circ Res 1966;19:851-9
18. Farhi ER, Cant JR, Barger AC. Interactions between intrarenal epinephrine receptors and the renal baroreceptors in the control of PRA in conscious dogs Circ Res 1982;50:447-52.
19. Gibbons GH, Dzau VJ, Farhi ER, Barger AC. Interaction of signals influencing renin release. Annu Rev Physiol 1984;46:291-7
20. Creager MA, Faxon DP, Rockwell SM, Gavras H, Coffman JD. The contribution of the renin-angiotensin system to limb vasoregulation in patients with congestive heart failure Observations during orthostasis and alpha-adrenergic blockade. Clin Sci 1985;68 659-71.
21. Kube SH, Cody RJ. Circulatory autoregulation in chronic congestive heart failure: responses to head-up tilt in 41 patients. Am J Cardiol 1983;52:512-17.
22. Mombouli JV, Varihoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1192;20(suppl 9): S974-82.
23. Valdemarsson S, Edvinsson L, Ekman R, Hedner P, Sjoholm A. Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors. J Intern Med 1991,230:325-31.
24. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensm I converting enzyme. Clin Exp Hypertens [A] 1987;9(2-3):243-59.
25. Horton R, Zinper R, Fichman M. Prostaglandins, renal function and vascular regulation. Med Clin North Am 1981;65:891-914
26. Zussman RM. Renin and nonrenin mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int 1984;25:969-83.
27. Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83.17774-7.
28. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-7
29. Kubes P, Suzuki M, Granger DN. Nitric oxide, an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
30. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE. A comparative study of the distributions of renin and angiotensmogen messenger nbonucleic acids in rat and mouse tissues. Endocrinology 1987;120 2334-8
31. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene Nature 1990;344:541-4.
32. Mendelsohn FAO, Allen AM, Chai SY, McKinley MJ, Oldfield BJ, Paxinos G. The brain angiotensin system. Trends Endocrinol Metab 1990;1:189-98.
33. Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn FAO. Localization of angiotensin converting enzyme in the rat heart Circ Res 1991;68:141-9.
34. Jackson B, Cubela R, Sakaguchi K, Johnston CI. Characterization of angiotensin converting enzyme (ACE) in the testis and assessment of the in vivo effects of the ACE inhibitor perindopril. Endocrinology 1988;123.50-5
35. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ. In situ hybridization evidence for angiotensin messenger RNA in the rat proximal tubule. J Clin Invest 1990;85:417-23.
36. Dzau VJ. Short- and long-term determinants of cardiovascular function and therapy contributions of circulation and tissue renin-angiotensin systems. J Cardiovasc Pharmacol 1989;14.S1-5.
37. Unger T, Gohlke P, Ganten D, Lang RE. Converting enzyme inhibitors and their effects on the renin-angiotensm system of the blood vessel wall J Cardiovasc Pharmacol 1989;13.S8-16.
38. Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin Il receptor subtypes. Biochem Biophys Res Commun 1989,165:196-203
39. Herblin WF, Chiu AT, McCall DE, et al. Angiotensin II receptor heterogeneity. Am J Hypertens 1991,4.299S-302
40. Timmermans PBMWM, Chiu AT, Herblin DM, Wong PC, Smith RD. Angiotensin II receptor subtypes. Am J Hypertens 1992;5:406-10.
41. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Arigiotensin II receptors and functional correlates. Am J Hypertens 1992;5.221S-35.
42. Murphy TJ, Takeuchi K, Alexander RW. Molecular cloning of AT1 angiotensin receptors. Am J Hypertens 1995;5 236S-42.
43. Kang PM, Landau AJ, Eberhardt RT. Angiotensin 11 receptor antagonists: a new approach to blockade of the reninangiotensin system. Am Heart J 1994;127:1388-401.
44. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM, Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992;32:133-65.
45. Tsutsumi K, Stromberg C, Sasvedra JM. Characterization of angiotensin II receptor subtypes in the rat spleen. Peptides 1992;13 291-6.
46. Regitz-Zagrosek V, Friedel N, Heymann A, et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 1995;91:1461-71.
47. 1 antagonists. J Cardiovasc Pharmacol 1995;26:66-72.
48. Regitz-Zagrosek V, Neuss M, Holzmeister J, Fleck E. Use of angiotensin II antagonists m human heart failure: function of the subtype I receptor. J Hypertens 1995;13 S63-71.
49. Katz AM. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 1994;121 363-71.
50. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992,20 301-6.
51. Olsen EN. Regulation of muscle transcription by the MyoD family. The heart of the matter. Circ Res 1993;72:1-6
52. Chien KR, Zhu H, Knowlton KU, et al. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993;55:77-95.
53. Tam SK, Gu W, Mahdavi V, Nadal-Ginard B. Cardiac myocyte terminal differentiation. Potential for cardiac regeneration. Ann NY Acad Sci 1995;752:72-9.
54. Komuro I, Kaida T, Shibazaki Y, et al. Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem 1990,265:3595-8.
55. Chidsey CA, Weinbach EC, Pool PE, Morrow AG. Biochemical studies of energy production in the failing human heart. J Clin Invest 1966;45:40-8
56. Sievers R, Parmley WW, James T, Coffelt-Wilman J. Energy levels at systole and diastole in normal hamster hearts vs. myopathic hamster hearts. Circ Res 1983;53:759-63.
57. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991;83:11-25
58. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22(suppl A):3A-5.
59. Cleland JGF, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double-blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985 54.305-12
60. Rousseau MF, Konstam MMA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting-enzyme inhibitor. Am J Cardiol 1994;73:488-93.
61. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin Il receptor antagonists VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:711-18.
62. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252: 719-25.
63. Merck and Co., Inc. Losartan potassium package insert. West Point, PA; 1995
64. Merck and Co., Inc. Clinical investigator's brochure. Losartan. West Point, PA; February 1995.
65. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure Circulation 1993,88.1602-9.
66. Crozier IG, Ikram H, Awan N, et al. Losartan in heart failure, hemodynamic effects and tolerability Circulation 1995;91: 691-7.
67. Levine TB, Olivari MT, Garberg V, Sharkety SW, Cohn JN. Hemodynamic and clinical response to enalapril, a long-acting converting enzyme inhibitor, in patients with congestive heart failure. Circulation 1984;69:548-53.
68. Raya TE, Fonken SJ, Lee RW, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 1991;4:334S-40.
69. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
70. Powers ER, Bannerman KS, Stone J, et al. The effect of captopril on renal, coronary, and systemic hemodynamics in patients with severe congestive heart failure. Am Heart J 1982;2:251-62.
71. Richard V, Berdeaux A, Giudicelli JF. Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs. J Cardiovasc Pharmacol 1993;22:52-7.
72. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984;53:105-8.
73. Mujais SK, Fouad FM, Tarazi RC. Reversal of left ventricular hypertrophy with captopril: heterogenicity of response among hypertensive patients. Clin Cardiol 1983;6:595-602.
74. Smits JF, van-Krimpen C, Schoemaker RG, Cleutjens JP, Daemen MJ. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1992;20:772-8.
75. Richard DP, Benedict CR, Kronenberg MW, et al. Effects of long-term enalapril on adrenergic activity and sensitivity during exercise in patients with left ventricular dysfunction. Circulation 1993;88:472-80.
76. Borghi C, Ambrosioni E. ACE inhibitors during and after myocardial infarction. SMILE pilot study working party [letter] Lancet 1990;335:1398.
77. Osterrieder W, Muller RKM, Powell JS, Clozel JP, Hefti F, Baumgartner HR. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension 1991;19(suppl II):II-60-4.
78. Prescott MF, Webb RL, Reidy MA. Angiotensin-converting-enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Am J Pathol 1991;139:1291-6.
79. Kawamura M, Terashita Z, Okuda H, et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimai thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 1993;266:1664-9.
80. Powell JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
81. Kim S, Kawamura M, Wanibuchi H, et al. Angiotensin II type 1 receptor blockade inhibits the expression of immediate early genes and fibronectm in rat injured artery. Circulation 1995;92:88-95.
82. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
83. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990,15: S65-72
84. Someya N, Morotomi Y, Kodama K, et al. Suppressive effects of captopril on platelet aggregation in essential hypertension J Cardiovasc Pharmacol 1984;6:840-3.
85. Moser LR, Callahan KS, Cheung AK, Stoddard GJ, Munger MA. ACE inhibitor effect on platelet dynamics in stage I-II hypertension: a class effect? Pharmacotherapy 1995;15:366.
86. Sica DA, Lo MW, Shaw WC, et al. The pharmacokinetics of losartan in renal insufficiency J Hypertens 1995;13:S49-52.